Physician profile
Ghulam Idrees
NPI 1447218292
$9,134.77
in general payments reported to CMS, 2019-2025
49 companies · $821 in 2025
The $821 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $1,466 · 2021: $1,405 · 2022: $1,304 · 2023: $991 · 2024: $1,344 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,156.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,177.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,009.96 | 2020-2025 | |
| Novo Nordisk INC | $921.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $890.35 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $610.78 | 2019-2025 | |
| Lilly USA, LLC | $473.38 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Glaxosmithkline, LLC. | $456.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $445.28 | 2021-2025 | |
| Astellas Pharma US INC | $352.38 | 2019-2025 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.50 | 2019-2025 | Jardiance, Spiriva Respimat |
| Amarin Pharma, INC. | $227.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $226.52 | 2019-2024 | Spravato |
| Amgen INC. | $153.90 | 2019-2025 | Evenity, Repatha, Otezla |
| Merck Sharp & Dohme LLC | $145.69 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $141.05 | 2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ghulam Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.